Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus

European Journal of Cancer

Volumn 50, Issue 16, 2014, Pages 2831-2837

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Diabetes; Epidemiology; Metformin; Prostate cancer; Taiwan

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COHORT ANALYSIS; DOSE TIME EFFECT RELATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TAIWANESE; TREATMENT DURATION; AGED; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; INCIDENCE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR; TAIWAN; TREATMENT OUTCOME;

ADULT; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 84925395989     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.08.007     Document Type: Article

References (26)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. C.H. Tseng Diabetes and risk of prostate cancer: a study using the National Health Insurance Diabetes Care 34 2011 616 621
3. C.H. Tseng Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men Ann Med 43 2011 142 150
4. K. Kato, J. Gong, H. Iwama, A. Kitanaka, J. Tani, and H. Miyoshi The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo Mol Cancer Ther 11 2012 549 560
5. J.L. Wright, and J.L. Stanford Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes Control 20 2009 1617 1622
6. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
7. D. Margel, D. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkarni, and P.C. Austin Association between metformin use and risk of prostate cancer and its grade J Natl Cancer Inst 105 2013 1123 1131
8. K.K. Tsilidis, D. Capothanassi, N.E. Allen, E.C. Rizos, D.S. Lopez, and K. van Veldhoven Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial Diabetes Care 37 2014 2522 2532
9. SGO Clinical Practice Endometrial Cancer Working Group W.M. Burke, J. Orr, M. Leitao, E. Salome, and P. Gehrig Endometrial cancer: a review and current management strategies: Part II Gynecol Oncol 134 2014 393 402
10. A. Hitron, V. Adams, J. Talbert, and D. Steinke The influence of antidiabetic medications on the development and progression of prostate cancer Cancer Epidemiol 36 2012 e243 e250
11. A.A. Onitilo, R.V. Stankowski, R.L. Berg, J.M. Engel, I. Glurich, and G.M. Williams Type 2 diabetes mellitus, glycemic control, and cancer risk Eur J Cancer Prev 23 2014 134 140
12. L. Azoulay, S. Dell'Aniello, B. Gagnon, M. Pollak, and S. Suissa Metformin and the incidence of prostate cancer in patients with type 2 diabetes Cancer Epidemiol Biomarkers Prev 20 2011 337 344
13. T.J. Murtola, T.L. Tammela, J. Lahtela, and A. Auvinen Antidiabetic medication and prostate cancer risk: a population-based case-control study Am J Epidemiol 168 2008 925 931
14. D. Soranna, L. Scotti, A. Zambon, C. Bosetti, G. Grassi, and A. Catapano Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Oncologist 17 2012 813 822
15. C.H. Tseng Pioglitazone and bladder cancer: a population-based study of Taiwanese Diabetes Care 35 2012 278 280
16. C.H. Tseng Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes Acta Diabetol 51 2014 295 303
17. R.B. D'Agostino Jr. Propensity scores in cardiovascular research Circulation 115 2007 2340 2343
18. K. Fall, H. Garmo, S. Gudbjörnsdottir, P. Stattin, and B. Zethelius Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden Cancer Epidemiol Biomarkers Prev 22 2013 1102 1109
19. M. Grossmann, and G. Wittert Androgens, diabetes and prostate cancer Endocr Relat Cancer 19 2012 F47 F62
20. C. Rothermundt, S. Hayoz, A.J. Templeton, R. Winterhalder, R.T. Strebel, and D. Bärtschi Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09) Eur Urol 2014 10.1016/j.eururo.2013.12.057 pii: S0302-2838(13)01482-6. PubMed PMID: 24412228 [Epub ahead of print]
21. D. Margel, D.R. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkarni, and P.C. Austin Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
22. M.Y. Lee, K.D. Lin, P.J. Hsiao, and S.J. Shin The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients Metabolism 61 2012 242 249
23. M.C. Hsieh, T.C. Lee, S.M. Cheng, S.T. Tu, M.H. Yen, and C.H. Tseng The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese Exp Diabetes Res 2012 2012 413782
24. T.T. Wu Should a prostate biopsy be advised for men with serum prostate-specific antigen levels of 2.5-4.0 ng/ml? JTUA 18 2007 135 138
25. Q. Li, S. Kuriyama, M. Kakizaki, H. Yan, T. Sone, and M. Nagai History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study Cancer Causes Control 21 2010 1025 1032
26. M.F. Leitzmann, J. Ahn, D. Albanes, A.W. Hsing, A. Schatzkin, and S.C. Chang Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial Cancer Causes Control 19 2008 1267 1276